Preferences of Dermato-oncologists for Adjuvant Therapy in Stage II Melanoma: A Nationwide Discrete Choice Experiment
DOI:
https://doi.org/10.2340/actadv.v105.44135Keywords:
conjoint analysis, immune checkpoint inhibitors, melanoma, treatment preferences, targeted therapyAbstract
Adjuvant treatment decisions in stage IIB/C melanoma require careful weighing of benefits and risks. Our aim was to investigate how dermato-oncologists in Germany prioritize efficacy, toxicity, and application mode of modern adjuvants in these stages. In a nationwide discrete choice experiment physicians evaluated hypothetical treatment scenarios that varied in recurrence risk, risk of severe adverse events, type of adverse events, and mode of administration. Two patient profiles were presented, including a 55-year-old healthy patient in stage IIB (P1) and an 83-year-old patient in stage IIC with comorbidity (P2). Physicians (n = 112) preferred adjuvant therapy to the opt-out option in 86.4% of scenarios for P1 and in 60.5% for P2. The risk of severe adverse events was considered most important for both patients and significantly more relevant for P2 (relative importance score (RIS) 53.6 vs 40.2, p < 0.001), while recurrence risk was more relevant for P1 (RIS 36.3 vs 21.8, p < 0.001). Immune-related adverse events were less acceptable than gastrointestinal symptoms or pyrexia. Infusions at longer intervals were favoured compared with oral therapies. In conclusion, dermato-oncologists prioritized safety over efficacy, particularly in the older, comorbid patient. These preferences should be reconciled with patients’ preferences and treatment goals during shared decision-making.
Downloads
References
Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, et al. Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325/KEYNOTE-054 trial. Eur J Cancer 2024; 211: 114327. DOI: https://doi.org/10.1016/j.ejca.2024.114327
Larkin J, Weber J, Del Vecchio M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. Eur J Cancer 2022; 173: 285–296. DOI: https://doi.org/10.1016/j.ejca.2022.06.041
Ascierto PA, Del Vecchio M, Mandala M, Gogas H, Arance AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol 2020; 21: 1465–1477. DOI: https://doi.org/10.1016/S1470-2045(20)30494-0
Long GV, Hauschild A, Santinami M, Kirkwood JM, Atkinson V, Mandala M, et al. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2024; 391: 1709–1720. DOI: https://doi.org/10.1056/NEJMoa2404139
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2022; 23: 1378–1388. DOI: https://doi.org/10.1016/S1470-2045(22)00559-9
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: final analysis of distant metastasis-free survival in the phase III KEYNOTE-716 study. J Clin Oncol 2024; 42: 1619–1624. DOI: https://doi.org/10.1200/JCO.23.02355
Luke JJ, Ascierto PA, Khattak MA, Rutkowski P, Del Vecchio M, Spagnolo F, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer 2025; 220: 115381. DOI: https://doi.org/10.1016/j.ejca.2025.115381
Kirkwood JM, Del Vecchio M, Weber J, Hoeller C, Grob JJ, Mohr P, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 2023; 29: 2835–2843. DOI: https://doi.org/10.1038/s41591-023-02583-2
Kirkwood JM, Mohr P, Hoeller C, Grob JJ, Del Vecchio M, Lord-Bessen J, et al. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. Eur J Cancer 2025; 220: 115371. DOI: https://doi.org/10.1016/j.ejca.2025.115371
Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, et al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment. J Clin Oncol 2022; 40: 3741–3749. DOI: https://doi.org/10.1200/JCO.22.00202
Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, et al. Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts. J Clin Oncol 2020; 38: 2543–2551. DOI: https://doi.org/10.1200/JCO.19.03034
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 2022; 399: 1718–1729. DOI: https://doi.org/10.1016/S0140-6736(22)00562-1
Patrinely JR Jr, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, et al. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol 2021; 7: 744–748. DOI: https://doi.org/10.1001/jamaoncol.2021.0051
van Akkooi AC, Hauschild A, Long GV, Mandala M, Kicinski M, Govaerts AS, et al. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB/IIC BRAF V600-mutated melanoma. Future Oncol 2023; 19: 2017–2027. DOI: https://doi.org/10.2217/fon-2023-0414
Garutti M, Bergnach M, Polesel J, Palmero L, Pizzichetta MA, Puglisi F. BRAF and MEK inhibitors and their toxicities: a meta-analysis. Cancers (Basel) 2022; 15. DOI: https://doi.org/10.3390/cancers15010141
Weilandt J, Diehl K, Schaarschmidt ML, Kieker F, Sasama B, Pronk M, et al. Patient preferences in adjuvant and palliative treatment of advanced melanoma: a discrete choice experiment. Acta Derm Venereol 2020; 100: adv00083. DOI: https://doi.org/10.2340/00015555-3422
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824–1835. DOI: https://doi.org/10.1056/NEJMoa1709030
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med 2018; 378: 1789–1801. DOI: https://doi.org/10.1056/NEJMoa1802357
Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017; 377: 1813–1823. DOI: https://doi.org/10.1056/NEJMoa1708539
Beusterien K, Middleton MR, Wang PF, Rao S, Kotapati S, Sabater J, et al. Patient and physician preferences for treating adjuvant melanoma: a discrete choice experiment. J Cancer Ther 2017; 08: 37–50. DOI: https://doi.org/10.4236/jct.2017.81004
Stellato D, Thabane M, Eichten C, Delea TE. Preferences of Canadian patients and physicians for adjuvant treatments for melanoma. Curr Oncol 2019; 26: e755–e765. DOI: https://doi.org/10.3747/co.26.5085
Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, et al. The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians. Oncotarget 2018; 9: 26217–26225. DOI: https://doi.org/10.18632/oncotarget.25439
Kähler KC, Gutzmer R, Angela Y, Livingstone E, Lodde G, Meiss F, et al. Preferences of physicians for treatment-related toxicity vs recurrence in melanoma (GERMELATOX-A): the doctors’ perspective. J Cancer Res Clin Oncol 2024; 150: 252. DOI: https://doi.org/10.1007/s00432-024-05713-6
Livingstone A, Dempsey K, Stockler MR, Howard K, Long GV, Carlino MS, et al. Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. BMC Cancer 2021; 21: 1014. DOI: https://doi.org/10.1186/s12885-021-08752-1
Beisel C, Poretta T, Sheppard VB, Hurtado-de Mendoza A, Sipsma H, Fuqua E, et al. Adherence to adjuvant therapy in patients with resected melanoma: an application of the theory of planned behavior. Adv Ther 2022; 39: 4061–4075. DOI: https://doi.org/10.1007/s12325-022-02221-2
Lodde G, Forschner A, Hassel J, Wulfken LM, Meier F, Mohr P, et al. Factors influencing the adjuvant therapy decision: results of a real-world multicenter data analysis of 904 melanoma patients. Cancers (Basel) 2021; 13: 2319. DOI: https://doi.org/10.3390/cancers13102319
Hoffmann M, Hayoz S, Ozdemir BC. Prescription patterns, recurrence, and toxicity rates of adjuvant treatment for stage III/IV melanoma: a real world single-center analysis. Biology (Basel) 2022; 11: 422. DOI: https://doi.org/10.3390/biology11030422
Mechow N, Peitsch WK, Diehl K, Ohletz J, Herz J, Eisert L, et al. Adjuvant treatment decisions of patients with stage IIB/C and III melanoma in routine clinical practice. Eur J Dermatol 2024; 34: 651–661. DOI: https://doi.org/10.1684/ejd.2024.4796
Published
How to Cite
License
Copyright (c) 2025 Amelie Kraaz, Wiebke K. Peitsch, Laura Ratusznik, Katharina Diehl, Christian Kromer, Dilan Akbarzadeh, Marthe-Lisa Schaarschmidt, Juliane Weilandt
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
